Literature DB >> 28532770

Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.

Pieter Martens1, Frederik H Verbrugge2, Petra Nijst1, Matthias Dupont2, Wilfried Mullens3.   

Abstract

Cardiac resynchronization therapy (CRT) improves cardiac hemodynamics. Therefore, the maintenance dose of loop diuretic therapy might be reduced. Consecutive patients who underwent CRT (n = 648) were retrospectively evaluated. Loop diuretic dose was recorded at baseline before implantation and 6 months later with patients classified into 4 groups: (1) no loop diuretic, (2) down-titration, (3) unchanged dose, and (4) up-titration. Afterward total loop diuretic exposure was calculated. Renal function trajectories were evaluated as the difference between implantation and censoring serum creatinine (Cr) value. Clinical outcome was evaluated as the combined end point of heart failure readmissions and all-cause mortality. Independent predictors of successful loop diuretic down-titration were identified. Two hundred ninety-six patients (46%) received no loop diuretic at follow-up, 126 (19%) underwent down-titration, 137 (21%) remained on a stable dose, and 89 (14%) underwent up-titration. In comparison with the group that was free from loop diuretics (Cr = +0.06 mg/dl), renal function deteriorated faster during follow-up in patients on stable doses (Cr = +0.29 mg/dl; p = 0.045) and those underwent up-titration (Cr = +0.44 mg/dl; p = 0.009) but not in patients who were down-titrated (Cr = +0.13 mg/dl; p = 1.00). Patients receiving down-titration had a lower risk for the combined clinical end point (adjusted hazards ratio 0.43; confidence interval 0.22 to 0.83; p = 0.012). Factors associated with successful down-titration after 6 months of CRT included nonischemic cardiomyopathy, higher baseline dose of diuretics, higher ejection fraction at 6 weeks, and lower right ventricular systolic pressure at 6 weeks. In conclusion, after CRT, down-titration of loop diuretics is often feasible and associated with improved outcome and a slower rate of kidney function decline. Patients with nonischemic cardiomyopathy, treated with high doses of loop diuretics before implantation and beneficial left ventricular remodeling with CRT, are most likely to tolerate loop diuretic down-titration.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28532770     DOI: 10.1016/j.amjcard.2017.04.021

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Loop diuretics in chronic heart failure: how to manage congestion?

Authors:  Justas Simonavičius; Christian Knackstedt; Hans-Peter Brunner-La Rocca
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 2.  Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

Authors:  Brian Kerr; Rebabonye B Pharithi; Matthew Barrett; Carmel Halley; Joe Gallagher; Mark Ledwidge; Kenneth McDonald
Journal:  Int J Heart Fail       Date:  2021-02-25

Review 3.  How to tackle congestion in acute heart failure.

Authors:  Pieter Martens; Wilfried Mullens
Journal:  Korean J Intern Med       Date:  2018-04-11       Impact factor: 2.884

4.  Insights into implementation of sacubitril/valsartan into clinical practice.

Authors:  Pieter Martens; Hanne Beliën; Matthias Dupont; Wilfried Mullens
Journal:  ESC Heart Fail       Date:  2018-02-21

5.  The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland.

Authors:  Thomas Ward; Tray Brown; Ruth D Lewis; Melodi Kosaner Kliess; Antonio Ramirez de Arellano; Carol M Quinn
Journal:  Pharmacoecon Open       Date:  2022-08-04

6.  Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose.

Authors:  Rebabonye B Pharithi; Maria Ferre-Vallverdu; Alan S Maisel; Eoin O'Connell; Myra Walshe; Claire Sweeney; James Barton; Kathrine McDonald; Daniel O'Hare; Chris Watson; Joe Gallagher; Mark Ledwidge; Kenneth McDonald
Journal:  ESC Heart Fail       Date:  2020-01-05

7.  Association of furosemide or hydrochlorothiazide use with risk of atrial fibrillation post pacemaker implantation among elderly patients.

Authors:  Da-Wei Lin; Feng Jiang; Chen Wu; Yi-Gang Li; Xi Zhang; Yao-Sheng Wang
Journal:  Ann Transl Med       Date:  2021-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.